Yanling Lv

1.7k total citations · 1 hit paper
62 papers, 1.2k citations indexed

About

Yanling Lv is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yanling Lv has authored 62 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Yanling Lv's work include Lung Cancer Treatments and Mutations (8 papers), Nutrition and Health in Aging (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Yanling Lv is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Nutrition and Health in Aging (5 papers) and Liver Disease Diagnosis and Treatment (5 papers). Yanling Lv collaborates with scholars based in China, United States and Sweden. Yanling Lv's co-authors include Tangfeng Lv, Dongmei Yuan, Yong Song, Xiaohui Miao, Liangkai Chen, Ping Zhan, Xiaokun Shen, Yuqing Wei, Shuang Rong and Ping Zhan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Yanling Lv

57 papers receiving 1.2k citations

Hit Papers

Global epidemiology of type 2 diabetes in patients with N... 2024 2026 2025 2024 10 20 30 40
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis
    2024 43 citations Limin Cao, Huiyuan Liu et al. BMC Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yanling Lv China 18 590 306 197 189 107 62 1.2k
Xi Yu China 23 547 0.9× 243 0.8× 202 1.0× 265 1.4× 116 1.1× 64 1.4k
Xiaohong Peng China 21 602 1.0× 344 1.1× 128 0.6× 234 1.2× 87 0.8× 61 1.4k
Shijie Wang China 20 507 0.9× 247 0.8× 289 1.5× 264 1.4× 127 1.2× 104 1.4k
Meng Fang China 20 456 0.8× 224 0.7× 119 0.6× 223 1.2× 212 2.0× 102 1.2k
Guoshuai Cai United States 19 659 1.1× 361 1.2× 116 0.6× 148 0.8× 100 0.9× 61 1.2k
Hongtao Wang China 23 736 1.2× 234 0.8× 94 0.5× 205 1.1× 218 2.0× 89 1.5k
Ke Ma China 22 623 1.1× 175 0.6× 232 1.2× 442 2.3× 114 1.1× 66 1.4k
Jianhua Xu China 21 389 0.7× 175 0.6× 222 1.1× 274 1.4× 117 1.1× 94 1.2k

Countries citing papers authored by Yanling Lv

Since Specialization
Citations

This map shows the geographic impact of Yanling Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanling Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanling Lv more than expected).

Fields of papers citing papers by Yanling Lv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanling Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanling Lv. The network helps show where Yanling Lv may publish in the future.

Co-authorship network of co-authors of Yanling Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Yanling Lv. A scholar is included among the top collaborators of Yanling Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanling Lv. Yanling Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yubin, et al.. (2025). Acetamiprid mediates cognitive dysfunction through the gut-brain axis: Synaptic damage and immune-mediated blood-brain barrier dysfunction. Journal of Hazardous Materials. 496. 139287–139287. 1 indexed citations
2.
3.
Lv, Yanling, et al.. (2025). Production of Recombinant Adeno-Associated Virus Through High-Cell-Density Transfection of HEK293 Cells Based on Fed-Perfusion Culture. Human Gene Therapy. 36(3-4). 116–127. 6 indexed citations
4.
Liu, Chao, Hui Xiong, Yanling Lv, et al.. (2025). Association of Physical Frailty With Incidence and Life Expectancy of COPD. CHEST Journal. 168(4). 890–900.
5.
Cao, Limin, Huiyuan Liu, Jinguo Jiang, et al.. (2024). Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Medicine. 22(1). 101–101. 43 indexed citations breakdown →
6.
Dai, Lei, et al.. (2024). Diabetes status, genetic susceptibility, and incident arrhythmias: A prospective cohort study of 457,151 participants. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 18(3). 102971–102971.
7.
Li, Yubin, et al.. (2024). Imbalance of mitochondrial quality control regulated by STING and PINK1 affects cyfluthrin-induced neuroinflammation. The Science of The Total Environment. 946. 174313–174313. 6 indexed citations
8.
Chen, Liangkai, Qiang Wang, Yanling Lv, et al.. (2023). Association of plasma advanced glycation end‐products and their soluble receptor with type 2 diabetes among Chinese adults. Diabetes/Metabolism Research and Reviews. 40(2). e3735–e3735. 8 indexed citations
9.
Lv, Yanling, Shuang Rong, Yan Deng, et al.. (2023). Plant-based diets, genetic predisposition and risk of non-alcoholic fatty liver disease. BMC Medicine. 21(1). 351–351. 24 indexed citations
10.
Lv, Yanling, Ding Ding, Mengyun Luo, et al.. (2023). Physical Activity Intensity, Genetic Predisposition, and Risk of Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. Clinical Gastroenterology and Hepatology. 21(13). 3444–3447.e2. 2 indexed citations
11.
Chen, Liangkai, Yanling Lv, Xiao Tan, et al.. (2023). Physical frailty, adherence to ideal cardiovascular health and risk of cardiovascular disease: a prospective cohort study. Age and Ageing. 52(1). 24 indexed citations
12.
Chang, Qing, Yixiao Zhang, Tingjing Zhang, et al.. (2022). Healthy Lifestyle and the Risk of Metabolic Dysfunction–Associated Fatty Liver Disease: A Large Prospective Cohort Study. SSRN Electronic Journal. 2 indexed citations
13.
Lv, Yanling, et al.. (2022). Association of Sleep Patterns and Lifestyles With Incident Hypertension: Evidence From a Large Population-Based Cohort Study. Frontiers in Cardiovascular Medicine. 9. 847452–847452. 13 indexed citations
14.
Zhou, Li, Yanling Lv, Zimu Wang, et al.. (2021). Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. Frontiers in Oncology. 11. 596542–596542. 8 indexed citations
15.
Chen, Liangkai, Wenwu Sun, Yanli Liu, et al.. (2021). Association of Early-Phase In-Hospital Glycemic Fluctuation With Mortality in Adult Patients With Coronavirus Disease 2019. Diabetes Care. 44(4). 865–873. 21 indexed citations
16.
Yuan, Dongmei, Qin Zhang, Yingshui Yao, et al.. (2016). Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials. Asian Pacific Journal of Cancer Prevention. 17(4). 1661–1675. 25 indexed citations
17.
Lv, Yanling, et al.. (2015). Expression and clinical significance of Oct-4 and E-cad in non-small-cell lung cancer. Oncology Letters. 11(1). 234–236. 8 indexed citations
18.
Lv, Yanling, Dongmei Yuan, Qingbo Wang, et al.. (2012). Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor. Medical Oncology. 29(4). 2633–2639. 6 indexed citations
19.
20.
Luo, Liang, Ting Zhang, Hongbing Liu, et al.. (2011). MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Medical Oncology. 29(3). 1681–1686. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xi Yu Breakdown of academic impact, for papers by Xiaohong Peng Breakdown of academic impact, for papers by Shijie Wang Breakdown of academic impact, for papers by Meng Fang Breakdown of academic impact, for papers by Guoshuai Cai Breakdown of academic impact, for papers by Hongtao Wang Breakdown of academic impact, for papers by Ke Ma Breakdown of academic impact, for papers by Jianhua Xu
Rankless by CCL
2026